Laurus Labs has notified the Bombay Stock Exchange and the National Stock Exchange of India Ltd. regarding a change in its directorate. The company’s Board of Directors, during a meeting held on July 24, 2026, took note of the retirement of Dr. Rajesh Koshy Chandy (DIN: 07575240) as an Independent Director. The retirement is effective from close of business hours on July 26, 2026, marking the conclusion of his second term in office, which spanned from July 27, 2021, to July 26, 2026.

The intimation was issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure aligns with the requirements set forth in SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026. G. Venkateswar Reddy, Company Secretary & Compliance Officer, signed the communication, confirming the procedural compliance with regulatory mandates.

Key Details of Director Change

The Board meeting commenced at 02.00 p.m. IST and concluded at 02.42 p.m. IST on July 24, 2026. The filing serves as a formal record of the cessation of Dr. Chandy’s tenure, ensuring transparency for shareholders and regulators regarding the composition of the Board.

Regulatory Compliance

The announcement was made pursuant to the mandatory disclosure norms for listed entities in India. By referencing the specific SEBI Master Circular, Laurus Labs confirmed that all requisite details regarding the reason for change, date of cessation, and term details were annexed to the filing. No new appointment was disclosed in this communication; the focus remains solely on the retirement of the outgoing director.

Laurus Labs delivered a standout financial performance in Q1, with consolidated revenue rising sharply to 20.3B rupees from 15.7B rupees in the year-ago period. Net profit more than doubled on a year-on-year basis to 3.7B rupees, well ahead of analyst estimates of 2.7B rupees, compared to a net profit of 1.63B rupees reported in the same quarter last year — marking a significant improvement in the company's bottom-line performance.

Strong Revenue and EBITDA Growth Drive Margin Expansion

The company's operational profitability saw a sharp uptick during the quarter, with EBITDA climbing to 6.44B rupees from 3.82B rupees in the year-ago period. Alongside the absolute growth in earnings, EBITDA margin expanded considerably, rising to 31.8% from 24.35% on a year-on-year basis, underscoring improved cost efficiencies and operating leverage.

The following table summarizes the key financial metrics for Q1:

Outperformance Against Analyst Estimates

Laurus Labs' Q1 consolidated net profit of 3.7B rupees came in significantly above the street estimate of 2.7B rupees, reflecting a notable beat on market expectations. The combination of strong revenue generation and margin expansion contributed to the earnings outperformance during the quarter.

Key Financial Highlights

• Revenue: 20.3B rupees vs 15.7B rupees (YoY)
• Consolidated Net Profit: 3.7B rupees vs 1.63B rupees (YoY)
• EBITDA: 6.44B rupees vs 3.82B rupees (YoY)
• EBITDA Margin: 31.8% vs 24.35% (YoY)
• Net Profit Estimate: 2.7B rupees — actual result exceeded estimate

Overall, Laurus Labs' Q1 results reflect a meaningful year-on-year improvement across all key financial metrics, with revenue, EBITDA, and net profit all registering strong gains. The margin expansion to 31.8% from 24.35% further highlights enhanced operational performance compared to the corresponding period last year.